### Clinical Practice Guidelines:
**In Development, Published, and Anticipated Future Topics**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Collaborative Society(ies)</th>
<th>Anticipated Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In Development</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiation therapy for brain metastases (replacement of 2012 guideline)</td>
<td>ASTRO, AANS/CNS, ASCO, SNO</td>
<td>Early 2022</td>
</tr>
<tr>
<td>Radiation therapy for lower grade gliomas</td>
<td>ASTRO, AANP, AANS/CNS, ASCO, SNO</td>
<td>Summer 2022</td>
</tr>
<tr>
<td>Radiation therapy for endometrial cancer (replacement of 2014 guideline)</td>
<td>ASTRO, ABS, ASCO, SGO</td>
<td>Fall 2022</td>
</tr>
<tr>
<td>Radiation therapy for oligometastatic disease for NSCLC</td>
<td>ASTRO, ESTRO</td>
<td>Late 2022</td>
</tr>
<tr>
<td>Accelerated partial breast irradiation (replacement of 2017 guideline)</td>
<td>ASTRO, ASCO, SSO</td>
<td>Spring 2023</td>
</tr>
<tr>
<td>Radiation therapy for HPV positive oropharyngeal squamous cell carcinoma (replacement of 2017 guideline)</td>
<td>ASTRO</td>
<td>Fall 2023</td>
</tr>
<tr>
<td>Bone Metastases (replacement of 2017 palliative RT for bone mets guideline)</td>
<td>ASTRO</td>
<td>Late 2023</td>
</tr>
<tr>
<td><strong>Collaborative Guidelines</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Locally advanced prostate cancer†</td>
<td>AUA, ASTRO, SUO</td>
<td>April 2022</td>
</tr>
<tr>
<td>Stage I and II non-small cell lung cancer</td>
<td>ACCP, ASTRO</td>
<td>2021</td>
</tr>
<tr>
<td>Vertebral augmentation of pathologic spine fractures</td>
<td>SIR</td>
<td>2022</td>
</tr>
<tr>
<td>Management of metastatic renal clear cell cancer</td>
<td>ASCO</td>
<td>2022</td>
</tr>
<tr>
<td>Esophageal cancer†</td>
<td>STS, ASTRO</td>
<td>2022</td>
</tr>
<tr>
<td>Breast reconstruction after mastectomy</td>
<td>ASPS, ASTRO</td>
<td>2022</td>
</tr>
<tr>
<td>Prevention and management of dysphagia in head &amp; neck cancer</td>
<td>AAO-HNSF</td>
<td>2022</td>
</tr>
<tr>
<td>Thoracic radiotherapy in patients having targeted therapies</td>
<td>IASLC, ASTRO, ESTRO, ESRS</td>
<td>2023</td>
</tr>
<tr>
<td>Salvage Therapy (replacement of RT after prostatectomy)†</td>
<td>AUA, ASTRO</td>
<td>2023</td>
</tr>
<tr>
<td><strong>Published Guidelines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of adults with brain metastases†</td>
<td>ASCO, ASTRO, SNO</td>
<td>December 2021</td>
</tr>
<tr>
<td>Management of stage III non-small-cell lung cancer</td>
<td>ASCO</td>
<td>December 2021</td>
</tr>
<tr>
<td>Radiation therapy for primary liver tumors</td>
<td>ASTRO, ASCO, ASTS, SIR, SSO</td>
<td>November 2021</td>
</tr>
<tr>
<td>Low-dose-rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement</td>
<td>ABS, ASTRO</td>
<td>September 2021</td>
</tr>
<tr>
<td>Radiation therapy for soft tissue sarcomas in adults</td>
<td>ASTRO, ASCO, MSTS, SSO</td>
<td>July 2021</td>
</tr>
<tr>
<td>Radiation therapy for rectal cancer</td>
<td>ASTRO, ASCO, SSO</td>
<td>October 2020</td>
</tr>
<tr>
<td>Metastatic carcinoma and myeloma of the femur†</td>
<td>MSTS, ASCO, AAOS</td>
<td>October 2020</td>
</tr>
<tr>
<td>Advanced prostate cancer</td>
<td>AUA, ASTRO, SUO</td>
<td>June 2020</td>
</tr>
<tr>
<td>Radiation therapy for cervical cancer</td>
<td>ASTRO, ASCO, SGO</td>
<td>May 2020</td>
</tr>
<tr>
<td>Hereditary breast cancer† (ASTRO radiation therapy summary – published June 2020)</td>
<td>ASCO, ASTRO, SSO</td>
<td>April 2020</td>
</tr>
</tbody>
</table>

Updated 3/2022
<table>
<thead>
<tr>
<th>Title</th>
<th>Society/Panel</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defining oligometastatic disease from a radiation oncology perspective</td>
<td>ESTRO, ASTRO</td>
<td>April 2020</td>
</tr>
<tr>
<td>Radiation therapy for small cell lung cancer</td>
<td>ASTRO</td>
<td>February/March 2020</td>
</tr>
<tr>
<td>Radiation therapy for basal and squamous cell skin cancer</td>
<td>ASTRO</td>
<td>December 2019</td>
</tr>
<tr>
<td>Radiation therapy for pancreatic cancer</td>
<td>ASTRO</td>
<td>September 2019</td>
</tr>
<tr>
<td>Margins for breast-conserving surgery with WBI in DCIS (reaffirmation of 2016 guideline)</td>
<td>SSO, ASTRO, ASCO</td>
<td>August 2019</td>
</tr>
<tr>
<td>Early stage testicular cancer</td>
<td>AUA</td>
<td>April 2019</td>
</tr>
<tr>
<td>Adjuvant and salvage radiation therapy after prostatectomy (update of 2013 guideline)†</td>
<td>AUA, ASTRO</td>
<td>April 2019</td>
</tr>
<tr>
<td>Hypofractionation for localized prostate cancer†</td>
<td>ASTRO, ASCO, AUA</td>
<td>November 2018</td>
</tr>
<tr>
<td>Palliative radiation therapy for NSCLC (update of 2011 guideline)</td>
<td>ASTRO</td>
<td>July 2018</td>
</tr>
<tr>
<td>Radiation therapy for the whole breast</td>
<td>ASTRO</td>
<td>May 2018</td>
</tr>
<tr>
<td>Stereotactic body radiation therapy (SBRT) for early stage NSCLC</td>
<td>ASTRO</td>
<td>September 2017</td>
</tr>
<tr>
<td>Radiation therapy for oropharyngeal squamous cell carcinoma</td>
<td>ASTRO</td>
<td>July 2017</td>
</tr>
<tr>
<td>Autologous breast reconstruction (endorsement, no representative)</td>
<td>ASPS</td>
<td>May 2017</td>
</tr>
<tr>
<td>Non-metastatic muscle-invasive bladder cancer</td>
<td>AUA, ASCO, ASTRO, SUO</td>
<td>April 2017</td>
</tr>
<tr>
<td>Clinically localized prostate cancer‡</td>
<td>AUA, ASCO, SUO</td>
<td>April 2017</td>
</tr>
<tr>
<td>Accelerated partial breast irradiation (update of 2009 guideline)</td>
<td>ASTRO</td>
<td>March 2017</td>
</tr>
<tr>
<td>Palliative radiation therapy for bone metastases (update of 2011 guideline)</td>
<td>ASTRO</td>
<td>January 2017</td>
</tr>
<tr>
<td>Postmastectomy radiotherapy (update of 2001 guideline)</td>
<td>ASCO, ASTRO, SSO</td>
<td>November 2016</td>
</tr>
<tr>
<td>Radiation therapy for glioblastoma</td>
<td>ASTRO, ASCO</td>
<td>July 2016</td>
</tr>
<tr>
<td>Role of postoperative radiation therapy for endometrial cancer</td>
<td>ASTRO</td>
<td>May 2014</td>
</tr>
<tr>
<td>Margins for breast-conserving surgery with WBI in stages I and II invasive breast cancer</td>
<td>SSO, ASTRO</td>
<td>March 2014</td>
</tr>
<tr>
<td>Definitive and salvage radiation therapy in NSCLC</td>
<td>ASTRO</td>
<td>June 2015</td>
</tr>
<tr>
<td>Radiotherapeutic and surgical management for newly diagnosed brain metastases</td>
<td>ASTRO</td>
<td>July 2012</td>
</tr>
</tbody>
</table>

**Future Topics**

<table>
<thead>
<tr>
<th>Title</th>
<th>Society/Panel</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmastectomy radiation therapy (PMRT)†</td>
<td>ASTRO, ASCO</td>
<td>2023</td>
</tr>
</tbody>
</table>

* The lead society is listed first for collaborative guidelines. ASTRO has at least one representative on each of these guideline panels.
† Full guideline partnerships.

Abbreviations: AAD, American Academy of Dermatology; AANP, American Association for Neuropathologists; AAO-HNSF, American Academy of Otolaryngology—Head and Neck Surgery Foundation; AAOS, American Academy of Orthopedic Surgeons; ACR, American College of Radiology; ACCP, American College of Chest Physicians; ADA, American Dental Association; ASCO, American Society for Clinical Oncology; AUA, American Urological Association; ESTRO, European Society for Radiation Oncology; ISOO, International Society of Oral Oncology; MASC, Multinational Association of Supportive Care in Cancer; MSTS, Musculoskeletal Tumor Society; ONS, Oncology Nurses Society; ASDP, American Society of Dermatopathology; SAR, Society of Abdominal Radiology; SGO, Society for Gynecological Oncology; SNMMI, Society of Nuclear Medicine and Molecular Imaging; SNO, Society of Neurological Oncology; SUO, Society for Urologic Oncology; and SSO, Society of Surgical Oncology.